AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05476237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Therapy for Adolescents (IPT-AG)
Description: IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
Study NCT05476237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
Study NCT05725486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-3 PUFAs Chicken Meet
Description: Intake of n-3 PUFAs enriched chicken meet for three weeks.
Study NCT05725486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular Chicken Meet
Description: Intake of regular chicken meet for three weeks.
Study NCT04907773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Capillary blood sampling
Description: Each subject will have one to two capillary blood collections.
Study NCT04907773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood sampling
Description: Each healthy subject will also have a reference venous blood collection.
Study NCT04907773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterio-venous blood sampling
Description: Each hemodialysed subject will also have a reference arterio-venous blood collection.
Study NCT05311995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only different trocar sites
Description: Only different trocar sites in literature
Study NCT05894720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Group
Description: the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs.
Study NCT05215249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified high-flow oxygen delivery
Description: The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
Study NCT05483088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
Study NCT05999682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apigenin
Description: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Study NCT05999682 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterilized water
Description: Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Study NCT05482620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic walking program
Description: Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
Study NCT05482620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational sessions and usual care
Description: Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
Study NCT05482620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational sessions and usual care
Description: Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
Study NCT05292209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG
Description: Riluzole 50mg tablets
Study NCT05292209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG
Description: Riluzole 50mg tablets
Study NCT06162052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation
Description: Technology will be used to enhance rehabilitation.
Study NCT06513819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique
Description: Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
Study NCT04981327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Description: Apixaban 5 MG BID versus Apixaban 2.5 MG BID
Study NCT04981327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Description: Apixaban 5 MG BID versus Apixaban 2.5 MG BID
Study NCT05602142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]CPPC PET ligand
Description: Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
Study NCT05697497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily exercise intervention
Description: Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
Study NCT05600816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pounce Venous Thrombectomy System
Description: The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
Study NCT05250076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination.
Study NCT06495047 — intervention group
Intervention type: DRUG
Intervention: Long-acting bronchodilator therapy (LABD)
Description: Long-acting inhaler therapy
Study NCT06495047 — intervention group
Intervention type: DRUG
Intervention: Short-acting bronchodilator therapy (SABD)
Description: Short-acting inhaler therapy
Study NCT05734625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
Study NCT05782699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP monitoring during tilt testing
Description: BP measure at various times during tilt testing
Study NCT05782699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP monitoring during tilt testing
Description: BP measure at various times during tilt testing
Study NCT04604652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 (BUDCA)
Description: HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
Study NCT05406947 — intervention group
Intervention type: OTHER
Intervention: Prospective observational study, no intervention
Description: Prospective observational study, no intervention
Study NCT05680857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
Study NCT05680857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product containing marine collagen peptide and Coenzyme Q10.
Description: Product containing marine collagen peptide and Coenzyme Q10.
Study NCT05734625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection
Description: Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
Study NCT06290167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 360° media
Description: sessions with head mounted display in hospital and sessions with tablet at home
Study NCT06290167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
Study NCT06290167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In hospital sessions
Description: sessions will be carried out under the supervision of a therapist
Study NCT06290167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: at home sessions
Description: sessions will be carried out without the supervision of a therapist
Study NCT06290167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mild Cognitive Impairment
Description: half of this group will perform the protocol with 360° videos and the other half will perform the TAU
Study NCT06290167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subjective Memory Complain
Description: half of this group will perform the protocol with 360° videos and the other half will perform the TAU
Study NCT05019612 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy: A minimal invasive surgery
Description: A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
Study NCT03448666 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
Study NCT05745987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavarian Nordic smallpox vaccine
Description: A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
Study NCT05745987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid VI Polysaccharide Vaccine Injectable Solution
Description: A single dose of the typhoid vaccine will be given at baseline.
Study NCT05677802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05677802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical cart review
Study NCT05677802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Management Therapy
Description: Receive biobehavioral stress reduction intervention
Study NCT05677802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05497349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukocyte Rich- PRP injection
Description: Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
Study NCT05497349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Poor- PRP injection
Description: Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
Study NCT05975515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft /Bone graft/ Customized HA
Description: Soft tissue management and augmentation
Study NCT05975515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft /Bone graft/ Customized HA
Description: Soft tissue management and augmentation
Study NCT06493721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clear Aligner Treatment
Description: Clear aligner therapy to treat incisors crowding
Study NCT06493721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Apply clear aligner therapy with low level laser application on incisors
Study NCT05421234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic test and sperm analysis
Description: Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test.
Study NCT06266949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SONDA
Description: Perimetry based visualfield analysis
Study NCT06604546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase
Description: 150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
Study NCT06604546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
Study NCT06599710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: AndoSanTM
Description: Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
Study NCT04986046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Plate Lite
Description: Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly.
Study NCT04986046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Home Plate
Description: Virtual Home Plate comprises two, 45-minute weekly sessions where parents work together with a study staff member to discuss the themes and prepare the components of a meal, including entrees, side dishes, and desserts.
Study NCT04986046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and Vegetable prescription
Description: All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
Study NCT04986046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable prescription
Description: All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
Study NCT06605443 — intervention group
Intervention type: DEVICE
Intervention: Breath analyzer
Description: The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
Study NCT06605443 — intervention group
Intervention type: DEVICE
Intervention: Skin patch
Description: A skin patch will be placed in the anterior part of the patient\&#39;s arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
Study NCT06605443 — intervention group
Intervention type: GENETIC
Intervention: Liquid biopsy
Description: Circulating free tumor DNA (cfDNA) will be extracted from patient\&#39;s blood and analyzed to detect mutations in BRAF and other prognostic genes.
Study NCT06600633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 14 days of intervention with Placebo Product (PP)
Description: 1 spray (0 mg melatonin)
Study NCT06600633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of intervention with Active Control (AC)
Description: 1 spray (1 mg melatonin)
Study NCT06600633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 14 days of intervention with Test Product (TP)
Description: 1 spray (0.3 mg melatonin)
Study NCT06601868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: R-Support Prepare & After nutritional supplement
Description: R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
Study NCT06605755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine
Description: The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age.
Study NCT06605755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine
Description: The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age.
Study NCT06606236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2O2 at 35% for 8 minutes
Description: The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
Study NCT06606236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2O2 at 40% for 20 minutes
Description: The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
Study NCT06606236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2O2 at 25% plus cold blue light for 15 minutes
Description: The investigators rigorously followed the manufacturer's instructions for all bleaching systems.